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Abstract There are several aerosolized drugs which have
been used in the treatment of neonatal respiratory illnesses,
such as bronchodilators, diuretics, and surfactants. Preclinical
in vitro and in vivo studies identified a number of variables
that affect aerosol efficiency, including particle size, aerosol
flows, nebulizer choice, and placement. Nevertheless, an
optimized aerosol drug delivery system for mechanically
ventilated infants still does not exist. Increasing interest in
this form of drug delivery requires more controlled and
focused research of drug/device combinations appropriate for
the neonatal population. In the present article, we review the
research that has been conducted thus far and discuss the
next steps in developing the optimal aerosol delivery system
for use in mechanically ventilated neonates.
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Introduction
Aerosols have been proven to be an effective form of drug
delivery. Nevertheless, the development of devices as well
as medical agents for aerosolization to treat intubated and
mechanically ventilated infants still presents a significant
challenge. Low tidal volumes (VT) and functional residual
capacity, high respiratory rates (RR), a shortened particle
residence time, and smaller airway diameters account for
the diminished delivery of inhaled aerosols to the lower
airways in these infants [15, 31, 33]. There are a limited
number of clinical deposition studies in the neonatal
population because of the inability to use radiolabeled
aerosols [24]. However, despite the paucity of clinical data,
aerosols have been used to treat critically ill newborn
infants without a clear understanding of the optimal aerosol
delivery system, the drug deposition pattern in the lung, and
the dose/response relationship for aerosolized medications.
Aerosolized medications are administered to infants with
ventilator support as part of routine therapy [6]. Historically,
regulatory approvals for the use of nebulizer and delivery
systems in the neonatal intensive care unit (NICU) have been
based on adult studies or in vitro simulations. In September
2007, the United States Congress passed Title III of the FDA
Amendments Act, The Pediatric Medical Device Safety and
Improvement Act, requiring that new applications or proto-
cols submitted to the FDA for the use and approval of a
medical device must include a description of any pediatric
subpopulation that suffers from the condition that the device
will treat, diagnose, or cure [68]. This Act prompted the
development of new aerosol generators for infants requiring
ventilator support [29] as the nebulizers and aerosol delivery
systems in use prior to the implementation of this Act were
not designed solely for this population.
Clinical studies with aerosolized agents in the NICU
Aerosolized drugs have been used routinely in the NICU
for several decades; however, the results of clinical studies
have been generally disappointing. Aerosolized agents were
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DOI 10.1007/s00431-010-1292-6first used in critically ill infants more than 40 years ago by
Robilliard et al. [59] who administered aerosolized
dipalmitoyl-phosphatidylcholine directly into the incubators
of premature infants with established respiratory distress
syndrome (RDS). In this non-controlled study, they found
that respiratory effort decreased in 8 of 11 infants. In
contrast, investigators at the University of California, San
Francisco, and the University of Singapore were unable to
demonstrate a physiological benefit with aerosolized phos-
phatidylcholine [13]. Other studies in which dipalmitoyl
lecithin aerosol was administered to infants with RDS were
also “negative” and discouraged the use of aerosolized
surfactant therapy for many years [39, 64]. However, in the
1990 s, clinicians once again became interested in aerosolized
surfactant therapy as noninvasive mechanical ventilation
became more prevalent in the neonatal population. The first
study in neonates, using nasal continuous positive airway
pressure (nCPAP) in combination with aerosolized surfactant
for treatmentofRDS,was conductedin1997.This wasa pilot
feasibility study in which preterm newborns with moderate
RDS requiring pharyngeal CPAP received nebulized SF-RI1
(Alveofact
®, Boehringer Ingelheim, Ingelheim, Germany)
[42]. The procedure was shown to be safe and the study
demonstrated that ventilation and oxygenation improved
once nebulization of surfactant was initiated. The following
year, Arroe et al. [5] tested the efficacy and safety of
nebulized colfosceril palmitate (Exosurf
®, GlaxoSmithKline,
Brentford, UK) delivered via nCPAP in preterm newborns.
The study reported no adverse effects, but did not demon-
strate any improvement in clinical efficacy variables as a
result of the treatment. Berggren et al. [8] treated 34
newborns (28–33 weeks post-conceptional age and 1,015–
2,370 g) with RDS using nCPAP and aerosolized poractant
alfa (Curosurf
®, Chiesi Pharmaceutici SpA, Parma, Italy).
The investigators were also unable to demonstrate the
superiority of aerosolized surfactant delivery over nCPAP
alone. Finer et al. [26], in a recent clinical study with
aerosolized lucinactant (Aerosurf
®, Discovery Laboratories
Inc., Warrington, PA, USA), tested the feasibility and safety
of delivering a peptide-containing synthetic surfactant to
newborns with early signs of RDS within 1 h of birth. This
study used a clinically approved vibrating mesh nebulizer,
the Aeroneb
® Pro (Aerogen, Dangan, Galway, Ireland), with
a specially designed CPAP adaptor which allows for aerosol
administration just below the “Y” connector. The procedure
was shown to be safe with a low occurrence of “peridosing
events” but lack of efficacy as there was not control group
included.
A wide variety of other aerosolized medications have
been studied in critically ill infants, demonstrating little to
no benefit. Shah et al. [63] published a review in the
Cochrane Library on the early administration of inhaled
corticosteroids for preventing chronic lung disease (CLD)
in ventilated very low-birth-weight infants. The meta-
analysis of seven trials found no evidence that the early
use of inhaled steroids prevents the development of CLD.
All of the studies included in this meta-analysis utilized
metered-dose inhalers (MDI), except one study by Jonsson
et al. [41] which used a dosimetric jet nebulizer for
corticosteroid aerosol generation.
There have been several small clinical studies conducted
focusing on the use of aerosolized diuretics for the
treatment of infants with developing or established CLD.
A recently updated Cochrane Review concluded that in
preterm infants older than 3 weeks of life with CLD, the
administration of a single dose of aerosolized furosemide
improved pulmonary mechanics. However, in view of the
lack of data from randomized trials concerning effects on
important clinical outcomes, routine or sustained use of
aerosolized loop diuretics in infants with (or developing)
CLD was not recommended [11]. Of the eight studies
comprising this review, only four indicated the type of
aerosol generator used: jet and ultrasonic.
The Cochrane Library also reviewed the use of aerosol-
ized bronchodilators for the prevention and treatment of
CLD. Only one study, in which CLD was a key clinical
outcome, met the criteria for inclusion in the analysis. This
double-blinded, multicenter randomized trial compared
inhaled beclomethasone in combination with salbutamol
vs. beclomethasone alone. There were no statistically
significant differences in mortality, CLD, need for paren-
teral dexamethasone, respiratory infections, or positive
blood cultures between the combination with salbutamol
and beclomethasone alone. Furthermore, there were no
statistically significant differences in the duration of
ventilatory support, duration of oxygen supply, or age of
weaning from respiratory support (defined as assisted
ventilation or oxygen supplementation) between the two
treatment groups [53].
Inhaled prostacyclin (PGI2) has been administered to
newborns with persistent pulmonary hypertension (PPHN)
[10, 43, 66] and to infants with PPHN following surgical
repair of congenital heart disease [12]. These studies
showed improvement in oxygenation due to the decrease
of intrapulmonary shunt after treatment with aerosolized
PGI2. Nevertheless, these observations were never con-
firmed by subsequent large multicenter randomized trials.
The clinical trials summarized above provide no clear
evidence of efficacy with aerosolized agents in the neonatal
population. Furthermore, different aerosol generators were
used in these studies. It is important to remember that residual
volumes vary among devices. Dubus et al. [23]r e p o r t e d
residual volumes of 0.1 and 1.1 mL for vibrating mesh and
jet nebulizers, respectively. Such factors as gas flows and
different output rates could influence the emitted dose. Thus,
variations in device characteristics among studies make it
434 Eur J Pediatr (2011) 170:433–444difficult to provide an objective comparison of clinical
outcomes.
Mechanical ventilation and aerosol delivery
Placement and type of the aerosol generator
There are only a few options for aerosol entrainment within
the ventilator circuit: (1) placement of the nebulizer within
the inspiratory arm of the circuit or (2) introducing the
aerosol between the “Y” connector and patient interface.
Connecting the nebulizer to the inspiratory arm via a “T”
shape connector is recommended for MDIs (Fig. 1a–d),
vibrating mesh nebulizers, and jet nebulizers (Fig. 2).
Entraining the aerosol between the “Y” connector and
patient interface is used mainly for MDIs with a holding
chamber (Fig. 3), although some recent studies have also
suggested the utility of the placement of vibrating mesh
nebulizers in this location whenever a nebulizer with a low
residual volume is used [19, 22, 29] (Fig. 4). The general
overview of clinically used aerosol generators as well as the
most critical variables influencing the effectiveness of
aerosolized formulations used for mechanically ventilated
infants are included in Table 1.
Fok et al. [31] compared different aerosol generators in
delivering salbutamol labeled with technetium-99m (
99mTc)
to infants with bronchopulmonary dysplasia (BPD). The
particle size (mass median aerodynamic diameter (MMAD)
and geometric standard deviation (GSD)) measured at the
end of the endotracheal (ET) tube generated by MDI placed
between “Y” and the ET tube via a holding chamber were
1.88±0.01 and 1.45±0.03 μm, respectively. When a jet
nebulizer (Side Stream; MedicAid, UK) with a gas flow
rate of 6 L/min was placed within the inspiratory arm of the
ventilator circuit, the aerosol MMAD was 0.83±0.01 μm
and the GSD was 1.69±0.02 μm. The aerosols delivered to
the infants by jet nebulization were significantly finer than
those delivered by MDI (p=0.005). Despite the larger
particle size, the MDI was associated with a significantly
higher pulmonary deposition relative to the jet nebulizer
when results were expressed as a percentage of initial
nebulizer reservoir activity (nominal dose; 0.19% vs.
0.08%, resp., p=0.009). These data suggest that for
intubated infants, smaller particle size at the aerosol
generator does not ensure a superior pulmonary deposition
and that the type and location of the nebulizer may also
influence the lung deposited dose. Dubus et al. showed that
the vibrating mesh nebulizer (Aeroneb Pro) was superior in
pulmonarydepositeddosewhencomparedtothe jet nebulizer
(MistyNeb; Airlife Inc., Montclair, CA, USA) when both
nebulizers were placed in the same location in the inspiratory
arm of the ventilator circuit with a MMAD of 1.4 μm
measured atthe end ofthe ET tube. This finding indicates that
device characteristics may drive clinical outcomes.
Based on Fok’s and Dubus’s findings, it appears that
aerosol entrainment into the ventilator circuit is as
important as particle size in lung deposition. In these
Fig. 1 Different options for MDI placement within ventilator circuit.
(From Dhand R, Tobin MJ: Bronchodilator delivery with metered-
dose inhalers in mechanically ventilated patients. Eur Respir J 9:585,
1996. With permission)
Fig. 2 In-line placement of the aerosol generator within the
inspiratory limb of the neonatal ventilator circuit. (From Aeroneb®
Solo System instruction manual (Aerogen))
ET tube Y′
′
Fig. 3 MDI placement between ‘Y’ connector and patient interface with
holding chamber. (Modified from Dhand R, Tobin MJ: Bronchodilator
delivery with metered-dose inhalers in mechanically ventilated patients.
Eur Respir J 9:585, 1996)
Eur J Pediatr (2011) 170:433–444 435studies, the jet and vibrating mesh nebulizers were placed
within the inspiratory limb of the ventilator circuit, whereas
the MDI was connected to the holding chamber placed
between the “Y” connector and the ET tube [31]. Entraining
the aerosol into the inspiratory arm of the circuit resulted in
considerable dilution of the aerosol because inspiratory flows
were much lower than the ventilator circuit flow rate
especially when a jet nebulizer was used with an additional
6 L/min gas driving flow. Furthermore, the use of higher
airflows in the ventilator circuit can lead to the impaction of
aerosol within the ventilator circuit before reaching the
patient. It is also possible that very small particles (below
1 μm) generated by the jet nebulizer (with relatively low
inspiratory flows) were exhaled, leading to reduced lung
deposition [56].
Valved holding chambers (VHC) are used in order to
optimize aerosol particle size generated by MDIs. The VHC
allows time and distance for particle shrinkage and also acts
as a large particle filter [20]. Removing the chamber may
increase the impaction of aerosol within the ET tube (up to
90% of the aerosolized dose) [58]. However, it is important
to remember that the placement of VHC, or even a “T”
connector between the “Y” connector and patient interface,
can increase ventilation dead space. Holding chambers can
also be placed within the inspiratory arm of the ventilator
circuit. Using a lung model, O’Doherty et al. [55]
demonstrated that such placement of the chamber increased
aerosol delivery due to continuous filling of the chamber
with aerosol during the exhalation phase of the breathing
cycle, but had no effect on particle size. It has also been
shown that electrostatic charge can have a major influence
on the delivery of salbutamol generated by MDI [72].
Nevertheless, coating the plastic chamber with an ionic
detergent solved the problem of electrostatic charge by the
buildup of a conducting layer on the chamber surface and
improved aerosol delivery from plastic VHC [72].
Placement of the nebulizer closer to the patient (between
the ET tube and the “Y” connector) avoids potential
dilution of the aerosol by the higher ventilator airflow
rates. Using a neonatal lung model, Turpeinen and
Nikander [69] demonstrated that placement of the nebulizer
at the ET tube level improved drug delivery compared to
in-line nebulizer placement within the inspiratory arm of
the ventilator circuit. Nevertheless, clinical studies with
Fig. 4 Placement of the mesh vibrating aerosol generator between ‘Y’
connector and ET tube. (Pulmonary drug delivery system (PDDS)
connects to low-volume adapter that is connected to patient interface.
This system optimizes the aerosol delivery to LRT in mechanically
ventilated patients (Aerogen))
Table 1 Characteristics of different aerosol generators used for ventilated infants
Jet Vibrating mesh Ultrasonic MDI
Principle
of aerosol
generation
Pressurized gas forms a
jet passing over a capillary
tube that draws liquid
formulation into the
jet stream
Aerosol is produced by
micropumping action
of the vibrating mesh
containing 1,000
funnel-shaped holes
Piezoelectric crystal converts
an electrical signal into
high-frequency vibrations
and creates a standing wave
in the medication and
produces aerosol
Active drug is suspended in
propellant which provides
the force to generate the
aerosol cloud when
released from the canister
Gas flow Active Passive Passive Passive
Location
within circuit
Inspiratory arm Inspiratory arm or between
“Y” and ET tube
Inspiratory arm Inspiratory arm or between
“Y” and ET tube
Residual
volume
Large Small Small VHC size
Aerosol
particle size
Depends on gas flow
and formulation
Depends on mesh
and formulation
Depends on formulation Depends on VHC size
and type
Aerosol
temperature
Low Ambient Ambient Ambient
Efficacy
expressed
as inhaled
dose % of
nominal dose
Lower Higher Mid Mid
ET endotracheal, “Y” wye ventilator circuit connector, VHC valve holding chamber
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lung deposition (<1% of the nominal dose) with placement
of the nebulizer closer to the patient [71]. Other studies
have demonstrated enhanced lung deposition with place-
ment of the nebulizer <30 cm from the “Y” connector
within the inspiratory arm. This suggests that ventilator
tubing can assume the function of an aerosol reservoir [38,
55]. However, such a distal placement of the nebulizer from
the patient does not allow for synchronizing aerosol
generation with the patient’s breathing pattern. Further-
more, the constant high ventilator gas flow within the
inspiratory arm of the circuit can lead to aerosol dilution
and impaction before reaching patients’ airways, as
mentioned previously.
A recently published in vitro study by Ari et al. using a
pediatric lung model reported two important findings. First,
they noted that the vibrating mesh nebulizer was superior to
a jet nebulizer in aerosol delivery when efficiency was
expressed as a percentage of the nominal dose inhaled.
Secondly, they noted that the inhaled dose was higher when
the mesh vibrating nebulizer was placed in proximity to the
ventilator, just before humidifier with pediatric ventilator
settings. Nevertheless, it should be noted that neonatal VT
values are significantly lower and ventilator bias flows are
usually higher due to potential leaks around uncuffed ET
tubes, leading to potential dilutions of the aerosol within
ventilator circuitry [5].
Insummary,ifaMDIisused,theVHCcanbeplacedeither
intheinspiratoryarmofthecircuitorbetween “Y”andtheET
tube. If a jet or vibrating mesh nebulizer is used, they should
be placed within the inspiratory arm; nevertheless, the exact
location should be determined by well-designed clinical
studies. The ventilator setting should be adjusted if additional
nebulizer driving gas flow is used. The vibrating mesh
nebulizer results in superior lung deposition of the drug, most
likely due to the smaller residual volume and low operational
gas flows.
Mode of ventilation
Ventilator settings may also play a role in aerosol lung
deposition. Fink et al. [27] studied the effect of different
modes of ventilation on aerosol delivery from an MDI
using an in vitro model. This allowed for a comparison of
controlled mechanical ventilation, assist control, pressure
support, and continuous positive pressure modes. The study
demonstrated significantly higher aerosol deposition within
the lower respiratory tract (LRT) with spontaneous breaths
under CPAP. Moreover, LRT deposition was linearly
related to the duty cycle (inspiratory time/total breath
duration). Andersen and Klausen [3] showed that in a
spontaneously breathing adult, the use of positive end
expiratory pressure (PEEP) with aerosolized albuterol
improved lung function better than delivering aerosol
without PEEP. Unfortunately, a similar analysis on venti-
lated infants was not performed. Hess et al. [36] studied the
relationship between albuterol delivery and pressure control
vs. volume control ventilation in vitro. Their study showed
that albuterol delivery using a nebulizer (continuous aerosol
generation) was affected by the inspiratory time and
inspiratory flow pattern. However, when a pressurized
MDI (intermittent aerosol generation) was used, aerosol
delivery was not influenced by the inspiratory flow pattern,
inspiratory time, or lung mechanics. The use of synchro-
nized nasal intermittent positive pressure ventilation might
lead to an improvement in aerosol delivery to the lower
respiratory tract, although this has not been proven in an in
vivo study.
Humidity
Standard of care ventilator support requires the delivery
of humidified and heated air to patients in order to avoid
drying the airway mucosa [60, 62]. Several in vitro
studies have investigated the relationship between humid-
ification and aerosol lung deposition. Miller et al. [49],
using different jet nebulizers (AeroTech II
®, CIS-US,
Bedford, MA, USA, and Portex
®, SIMS Portex, Inc., Fort
Myers, FL, USA) and three different ventilators designed
for adults (with a driving flow of 8 L/min), demonstrated
that aerosol delivery increased nearly twofold (p<0.0001)
by turning off and bypassing the humidifier. In addition,
humidity increased the particle size at the tip of the ET
tube from 1.5±0.1 to 2.3±0.2 μm( p=0.0006) by
hygroscopic growth, suggesting greater particle impaction
in the ventilator tubing. Likewise, other studies showed an
approximate 40% decrease in aerosol lung deposition
when humidified and heated air was used [27, 32, 56].
Although studies were conducted under ventilated adult
conditions, conclusions related to humidity are applicable
to mechanically ventilated infants.
Aerosol conditioning for neonatal applications
Air flow
Jet nebulizers use airflow to generate the aerosol. Different
commercially available jet nebulizers have different airflow
parameters in order to reach optimized performance.
Ultrasonic or mesh vibrating nebulizers need gas flow in
order to entrain and carry aerosol toward the patient,
although airflow is not required to generate the aerosol
[35]. Coleman et al. [16] tested different nebulizer airflows
in combination with mechanical ventilation in a lung model
with settings selected to simulate a 4-kg infant with
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(Airlife™ Misty-Neb™ Baxter, Valencia, CA, USA) was
used in this study and was positioned in the inspiratory arm
of the ventilator circuit. The study demonstrated that as the
nebulizer airflow increased, delivery to the lung model
significantly decreased in a linear fashion; the mean percent
delivery at 5 L/min was 4.8±1.3%, whereas increasing the
flow to 6.5 L/min significantly decreased the mean percent
deliveryto3.7±1.1%.Furtherincreasingtheflowto8.0L/min
resulted in a significant decrease in the mean percent delivery
to 2.7 ± 1.1% (p<0.015 vs. 5 L/min). This study also
demonstrated higher aerosol deposition within the inspiratory
arm of the ventilator circuit with higher airflows, which was
most likely related to impaction. Similar relationship between
aerosol inhaled dose and ventilator bias flow was also
reported by Ari et al. [4]. Using a premature infant nose–
throat model, Minocchieri et al. [51] showed that higher
aerosol flows lead to reduced lung deposition. There was a
statistically significant decrease in aerosol delivery from
61.8±5.3% to 26.0±1.5% and 9.0±0.8% of nominal dose for
1, 5, and 10 L/min of inspiratory flow, respectively. An
important limitation of this study was the utilization of a
continuous airflow through the upper airway model rather
than a variable flow model that would have mimicked the
patients’ breathing pattern.
These in vitro studies have demonstrated that increased
airflow presumably leads to increased aerosol impaction in
the upper airways, resulting in decreased drug delivery and
deposition in the lungs. The use of in vitro models has been
shown to provide an acceptable assessment of delivery in
vivo [33, 71].
Breath-actuated aerosol generation
Synchronization of nebulizer actuation with the patient’s
breathing pattern allows for significant reduction of drug
losses during exhalation and has been shown to improve the
inhaled dose in adult patients [49]. Thus, whenever drug
deposition is presented as values of inhaled mass as a
function of nominal dose, the values will be improved. A
study conducted by Turpeinen and Nikander [69] using a
test lung mimicking a ventilated premature infant showed
that breath-synchronized nebulization and placement of the
nebulizer directly below the “Y” connector resulted in a
significantly higher deposition on the inspiratory filters
when the deposited dose was expressed as part of the
nominal dose. In contrast, non-synchronized nebulization
and aerosol generator placement within the inspiratory arm
of the ventilator circuit resulted in a lower deposited dose.
Nevertheless, it is not clear if these observations are an
effect of the nebulizer location, breath synchronization, or
type of the nebulized formulation [69]. There is only one
animal study evaluating the effectiveness of breath-
synchronized nebulization on LRT drug delivery to venti-
lated infants. Dubus et al. [23] compared lung deposition of
radiolabeled aerosol generated by three different delivery
systems (Misty-Neb with continuous mode and Aeroneb
Pro with and without breathing actuation) in macaque
monkeys. Surprisingly, the results did not show any
significant difference in the deposited dose in the lung
between synchronized and continuous nebulization (14%
vs. 12.6% of the nominal dose, respectively). Nevertheless,
the deposition values achieved in this study are higher than
those previously reported by other investigators.
Infants, especially preterm infants, pose a significant
technological challenge in this particular area because of
high respiratory rates (RR) and short inspiratory times (IT)
[15]. Moreover, flow and pressure-based sensors can be
damaged by aerosols, and their placement within the
aerosol flow and in close proximity to the patient is not
advisable. However, there are other technologies that can be
used for breath-synchronized nebulization such as Graseby
pneumatic capsule (Graseby Dynamics Ltd., Watford, UK)
[40] or neurally adjusted ventilator assist technology
(Maquet Inc., Bridgewater, NJ, USA) [65]. Neither of these
methods requires sensors placed within the ventilator tubes
and thus do not cause additional risks for aerosol impaction.
Breath-synchronized nebulization could potentially im-
prove drug delivery compared with continuous nebulization
by limiting drug loss during exhalation [54]; nonetheless,
there is a need for more in vivo data from ventilated infants.
Particle size
Recent studies of aerosol lung deposition in term and preterm
infants have used an indirect method to assess lung deposition
using a marker substance, sodium cromoglycate, which can be
measured in the urine. Kohler et al. [44] compared aerosol
delivery to non-intubated spontaneously breathing infants
using three different nebulizers: jet nebulizer (LC Star
®;P a r i ,
Starnberg, Germany), ultrasonic nebulizer (LS 290
®;S y s t a m ,
Villeneuve sur Lot, France), and ultrasonic nebulizer
(Projet®; Artsana, Grandate, Italy). During the aerosol dosing,
sleeping infants breathed through a face mask covering both
the mouth and nose. The highest lung deposition was noted
for LC Star jet nebulizer compared with the LS290 and Projet
nebulizers (0.089±0.036 vs. 0.055±0.019 and 0.046±
0.025 mg, respectively). The LC Star jet nebulizer used the
highest flow rate (7.55±0.18 L/min) and had the highest mass
percentage of droplets below 2 μm (20.3±0.7%). The amount
of sodium cromoglycate retained in each nebulizer after
testing was significantly higher for Projet nebulizer. The
authors concluded that for spontaneously breathing infants,
fine aerosol particles (<2 μm) are more likely to reach the
lower airways. Nevertheless, the higher deposited dose from
LC Star might also be a function of the smaller nebulizer’s
438 Eur J Pediatr (2011) 170:433–444residual volume and not only related to particle size.
Furthermore, the level of cromoglycate in the urine does not
give direct indication of lung deposition.
Although the LC Star had the highest lung deposition
among the other nebulizers, only 0.89% of the nominal
dose was deposited in the lungs after inhalation via LC Star
[44]. This finding is supported by other studies on infants
showing pulmonary deposition of <1% of the nominal dose
for spontaneously breathing and mechanically ventilated
patients [2, 33]. Significantly greater direct lung deposition
was reported in an in vivo study done on intubated and
mechanically ventilated macaque monkeys with the use of
Aeroneb Pro and
99mTc diethylenetriamine pentaacetate. In
this study, Dubus et al. [23] reported aerosol with MMAD
of 1.4 μm at the tip of the ET tube for both tested devices
but a 25-fold greater lung deposition of radiolabeled aerosol
when generated by Aeroneb Pro synchronized with inspi-
ration vs. Misty Neb in continuous mode (14% vs. 0.5% of
the nominal dose, respectively). These observations from
clinical and non-clinical studies indicate that fine particle
sizes that bypass artificial airways and upper airways can be
effectively delivered into the lungs of ventilated patients
and that differences in residual volumes between nebulizers
can drive deposition rates if they are expressed as percent of
nominal dose.
However, at the same time, small particles in combina-
tion with short (ITs) and low inspiratory flows increase the
risk of exhalation drug losses. Fok et al. [31] demonstrated
inferior lung deposition in infants with BPD treated with
smaller aerosol particles (MMAD of 0.83±0.01 μm) vs.
larger aerosol particles (MMAD of 1.88±0.01 μm). It has
been shown that small particles (<1 μm) are less dependent
on gravitation and can be exhaled without deposition in the
lungs. Calculations as well as actual measurements based
on adult models have indicated that particles between 2 and
6 μm are deposited in central airways and those above
6 μm are deposited in the oropharynx [21]. Studies
evaluating particle size delivery to the upper airway of the
preterm infants are limited. Minocchieri et al. [50], using an
upperairwaymodelcomparabletoa32-weekgestationinfant,
reported similar results. In this study, the average MMAD of
budesonideparticleswhichpassedupper airways was1.6 μm.
However, model-based studies do not account for amounts of
exhaled drug and the results are reflecting only theoretical
assumptions that should be supported by in vivo experiments.
O’Riordan et al. [56] showed that the majority of the
deposition within the tracheostomy tube occurred during
the exhalation phase of the breathing cycle, suggesting that
a significant fraction of inhaled aerosol was actually
exhaled. Intubated adults were mechanically ventilated
and treated with saline labeled with
99mTc bound to human
serum albumin. Aerosol was generated with jet nebulizer
AeroTech II and entrained into the inspiratory arm of the
ventilator circuit with a MMAD of 1.1 μm and GSD of
1.8 μm. The study reported that 53% of the total inhaled
dose was deposited in the lung, with the remainder of the
dose exhaled and deposited in the tracheostomy tube or
expiratory arm of the circuit [56]. Although this study was
conducted in ventilated adults, the results might be of
importance for ventilated infants for whom short inspiratory
times are likely to increase the risk of exhalation losses.
Heyder et al. [37] demonstrated that only 20–30% of the
submicron aerosol passing beyond the mainstem bronchi
was ultimately retained in the lungs; the remainder was
expired.
In summary, for intubated and non-intubated infants who
require breathing support, the most critical variable influ-
encing particle size is patient interface. The particles should
be small enough to bypass that interface with minimal
impaction losses, but should not be too small in order to
avoid significant exhalation losses. It is important to
remember that particle size is only one of many variables
that can influence pulmonary drug deposition. Others
include: output rate, driving flow rate, and device residual
volume.
Type of nebulized formulation
Turpeinen and Nikander [69] have reported significant
improvements in the emitted dose at the ET tube when
synchronized nebulization was used with the aerosol
generator placed close to the ET tube vs. continuous
nebulization with the generator placed within the inspira-
tory arm of the neonatal ventilator circuit. Interestingly, it
was also reported that irrespective of nebulizer synchroni-
zation and placement, a solution of terbutaline was superior
to a suspension of budesonide in terms of emitted dose
through an ET tube. The authors concluded that a solution
preparation was superior to a suspension in terms of drug
delivery via an ET tube.
Surfactants represent a significantly different class of
pharmaceutical agents due to chemical characteristics as
well as biophysical activity. Some studies suggest that
aerosolized surfactants may be associated with improved
pulmonary distribution when compared to a standard liquid
intratracheal instillation. Wagner et al. [70] demonstrated in
an intubated animal model that atomized surfactant with a
droplet size of 120±4 μm, administered to the trachea via a
catheter, achieved better distribution in the lungs than liquid
bolus instillation. Wagner’s results suggest that large
particles of aerosolized surfactant when passed through
vocal cords forma filmatthe air/liquidinterface thatspreadto
the alveoli along the surface tension gradient. Marcinkowski
etal.[46] showed that compared to saline, the dispersion area
of an aerosolized surfactant was significantly improved after
deposition onto mucus or epithelial cell culture surfaces. This
Eur J Pediatr (2011) 170:433–444 439finding further suggests that with aerosolized surfactant,
there is no need to aim the terminal airways as the final
target for delivery. The ability of surfactants to spread
along mucosal surfaces suggests a special role for them as
potential carriers for different aerosolized agents, which can
lead to improved lung deposition and more uniform drug
distribution.
Finer et al. [26] recently showed that highly viscous
solutions such as surfactants may influence nebulizer output
rates, in turn, leading to suboptimal emitted dose. These
findings indicate the need for the additional testing of
drugs with various devices.
Upper airways and gastric deposition
Aerosol deposition in the upper airways presents a
continuous challenge for pulmonologists. Amirav et al.
[2] studied spontaneously breathing, wheezing infants (1–
19 months of age) who received radiolabeled aerosolized
salbutamol (Ventolin
®, GlaxoSmithKline) with an MMAD
of 4.2 μm. The results showed that total lung deposition
varied from 2.4% to 2.6%, while a statistically significant
and clinically relevant benefit was observed among treated
patients, as reflected in improved oxygen saturation and
reduced respiratory rate. The authors also noted that in
addition to local oropharyngeal deposition, any aerosol
deposited in the upper respiratory tract was subsequently
swallowed and detected in the gastrointestinal tract,
accounting for 7.6% to 8.4%. This observation is impor-
tant for future development of aerosol therapies and
demonstrates the need for the accurate determination of
gastrointestinal tract losses.
Impaction of aerosol in upper airways can be limited or
avoided by generating small aerosol particles or by bypassing
this anatomical region, e.g., by using a nasopharyngeal tube
[47]. The nasal cavity with or without ciliated epithelium
acts like a filter and can limit the aerosol delivery into the
lower airways [7, 61]. In this regard, Jorch et al. [42]
bypassed the upper airways with a single nasal pharyngeal
(SNP) tube and showed that aerosolized surfactant combined
with CPAP significantly decreased the alveolar–arterial
oxygen gradient ((A-a)O2), Silverman score, and PaCO2 in
comparison to treatment with CPAP alone. Although this
was a small pilot study, the utilization of an SNP tube for
CPAP delivery has been applied in other neonatal clinical
trials [52, 67] and holds a potential to be a very useful
approach for aerosol delivery.
Table 2 summarizes all variables presented above that can
influence inhaled dose while the infant is on mechanical
ventilation.
Inhaled dose calculations
Each aerosolization system has its own characteristics of the
emitted dose and aerosol concentration. The delivered dose is
the amount of the drug dispensed from the device to the
patient (available to the patient) per minute and is called the
emitteddose(Ed). Aerosol concentration (C) is the amount of
the drug per gas carrier volume, which depends on peak
inspiratory flow (PIF) [21]. Assuming that an aerosol
generator has a constant output rate, the amount of the drug
available to the patient can be regulated by the length of
treatment. The inhaled dose is the amount of the drug
inspired by a patient during the breathing cycle; it is not the
same as the deposited dose. The variables that will determine
the amount of drug inhaled by a patient include: minute
ventilation (Vm, tidal volume and respiratory rate) [15],
aerosol concentration [47], and length of treatment. Vm
increases with patient size, although the value per body
Table 2 Factors influencing inhaled dose in mechanically ventilated infants
Mechanical ventilation-dependent Aerosol generator-dependent Formulation-dependent
↑ Inhaled dose ↓ Inhaled dose ↑ Inhaled dose ↓ Inhaled dose ↑ Inhaled dose ↓ Inhaled dose
CPAP IMV MMAD=1–3 μm MMAD<1 and >3 μm Aqueous solutions Viscous solutions
Bigger VT Smaller VT Small residual volume Large residual volume Solutions Suspension
Lower RR Higher RR MDI with VHC MDI without VHC Temperature=36°C Temperature <36°C
Longer IT Shorter IT Detergent coated VHC Non-coated VHC
Larger ET tube Smaller ET tube Aerosol flow=PIF Aerosol flow> or <PIF
Dry gas Humid gas Synchronized
actuations/release
Non-synchronized
actuations/release
Low ventilator
bias flow
High ventilator
bias flow
CPAP continuous positive airway pressure, IMV intermittent mechanical ventilation, MMAD mass median aerodynamic diameter, VT tidal volume,
RR respiratory rate, MDI metered dose inhaler, VHC valve holding chamber, ET endotracheal, PIF peak inspiratory pressure
440 Eur J Pediatr (2011) 170:433–444weight remains constant for relatively wide neonatal weight
ranges [9]. Based on these assumptions, the inhaled dose can
be presented as:
Inhaled Dose ¼ C mg L1 
  Vm½Lmin 1kg 1  T min ½ 
where C (aerosol concentration) is based on the emitted
dose from the system under known flow conditions and
Vm (minute ventilation) is related to the size of the infant.
Vm can be calculated based on direct neonatal lung
function measurements of spontaneously breathing
newborns as presented by Bhutani and Sivieri [9]. T
(length of treatment) is the external factor determining the
inhaled dose.
This calculation is applicable when two conditions are
met: first, a reliable aerosol generator capable of providing
a constant output rate must be used. This has been a
technical challenge as some off-shelf devices fail to provide
constant output rate based on performance testing [16];
second, the aerosol flow rate must equal or exceed the peak
inspiratory flow in order to avoid any potential aerosol
dilution during the inspiratory phase of the breathing cycle
[47].
Based on the calculation for inhaled dose, the deposited
dose in the LRT will be equal to the inhaled dose minus
the sum of the potential losses at the upper airways [7, 30,
61] and exhaled amount of the drug [37, 56]. Data on
aerosol deposition in the neonatal population are very
limited (and in premature and ventilated populations do not
exist), preventing accurate calculations of delivered doses
to the lung.
Other considerations
Ventilation gases
Any gas density lower than air or oxygen can reduce
airflow turbulence through the narrow airways of the
neonate. Fink et al. [28] found that aerosol delivery via a
MDI showed a linear increase when the gas density within
the ventilator circuit was decreased. The use of an 80%
helium and 20% oxygen mixture in a dry ventilator circuit
resulted in a 50% increase in the amount of drug delivered
to the lower respiratory tract compared with that observed
with 100% oxygen (46.1% vs. 30.4%), respectively [18].
However, it is important to remember that airflow-based jet
nebulizers may potentially exhibit decreased output rates
when used with helium–oxygen mixtures [22]. Interestingly,
noninvasive heliox ventilation has been recently shown to
decrease resistive work of breathing and ventilator support
requirements as well as improve gas exchange in premature
infants [48].
PEEP valve and ambient air contamination
An important technical issue that needs to be considered when
aerosol delivery is combined with mechanical ventilationis the
potential for contamination of the ventilator PEEP valve with
aerosolized agents exhaled by patients. Haas et al. [34]
evaluated the efficiency of a supplemental filter system
during mechanical ventilation for continuous nebulization of
a synthetic surfactant. The results showed that increased filter
resistance occurred at 7.3±1.3 h of continuous ventilation
with a minute ventilation of 20 L/min. This study also
demonstrated the need for an appropriate and continuous
pressure monitoring upstream to the expiratory filter in order
to detect the increase in baseline pressure associated with
expiratory filter occlusion.
Patient interface
Patient interface can also act as a significant site of aerosol
impaction. In an in vitro study, Ahrens et al. [1] investigated
the influence of different neonatal ET tube sizes and flows
on aerosol deposition in a test lung. The results suggested
that aerosol flows were more important than ET tube size on
aerosol deposition of conventional aerosols in clinical use
(MMAD=3.95 μm). The study also showed that test lung
deposition significantly improved when submicronic aerosol
(MMAD=0.54 μm) was delivered. Crogan and Bishop [17]
showed that the percentage of aerosolized metaproterenol
(Alupent
®, Boehringer Ingelheim) exiting the ET tube almost
doubled for a 9.0- vs. 6.0-mm ET tube. Everard et al. [25]
showed a drop in drug delivery when using a smaller ET
tube (2.5 vs. 3.0 mm) during in vitro testing of Babylog
Draeger neonatal ventilator circuit, and Dubus et al. [23]
reported that regardless of different aerosol particles at the
nebulizer outlet, the particle size distribution at the end of the
3.0-mm ET tube was similar with an MMAD of 1.4 μm
across all tested nebulizers.
As mentioned earlier, these findings show that patient
interface can be a critical variable determining the particle
size delivered to a mechanically ventilated patient [23].
Unfortunately, there are limited data on the influence of
neonatal ET tube size on aerosol characteristics and lung
deposition in in vivo studies.
Method of particle size measurement
Although research methodology was not the focus of this
review, it is important to point out some nuances related to
the methods of particle size measurement as each method
has its limitations that could potentially influence the results
and conclusions of the studies discussed in this review.
There are two generally approved methods to measure
particle size. The first, light-scattering techniques including
Eur J Pediatr (2011) 170:433–444 441laser diffraction analysis and single-particle counters, are
used primarily for aqueous solutions and wet aerosols.
Recently, the laser diffraction method has been proven to be
an acceptable tool for both wet as well as dry aerosols [57].
However, this method lacks resolution for aerosols on the
order of 1 μm. In addition, laser diffraction cannot be
applied to suspensions since this method measures droplet
size and is unable to determine which droplets contain drug
particles [14]. The second method for particle size
measurement is based on inertial impaction via cascade
impactors used for dry powder aerosols [14]. Cascade
impactors operate under high airflow conditions, making
this method less applicable to neonatal breathing condi-
tions. The resulting particle size measurements from
cascade impactors are temperature-related, with the possi-
bility of re-entrainment of bounced particles from the plates
whichcouldoverestimatetheratioofsmallerparticles[14, 45].
We did not analyze the methods used to determine particle
size measurement in the presented studies (some of these
studies did not address this information). Nevertheless, we
acknowledge that the method utilized for particle size
measurement could potentially affect the conclusions of some
of these studies.
Summary
Aerosol therapy is routinely used in critically ill neonates
despite lack of supporting data from randomized clinical
studies. Clearly, there are numerous factors known to
contribute to the performance of aerosol delivery systems.
Yet, to date, aerosol delivery systems have not been
systematically evaluated or approved for use in mechani-
cally ventilated, premature infants. Moreover, prescribing
information for currently available aerosolized medications
does not contain adequate information on dosage regimens
for premature infants. Of particular concern is the fact that
therapeutic index, including potential side effects from
upper airway or gastrointestinal deposition, has not been
adequately characterized.
Based upon what we have learned from the literature,
future research in this area should focus on designing
appropriate aerosol delivery systems for ventilated neonates
that efficiently entrain aerosols without impairment of
ventilatory support. For example, (1) inhalation chambers
should have an optimal volume or separated inhalation and
exhalation pathways to avoid re-breathing if placed be-
tween “Y” and the ET tube; (2) aerosol generator location
should be specified for certain types of generators, but its
placement should minimize potential aerosol dilutions; (3)
aerosol flows and particle size should be adjusted to the
infant’s breathing pattern and minute ventilation to limit
any drug losses in the upper airways; (4) aerosol delivery
systems including generator should be single-use or re-
sterilized after use to avoid any potential infectious hazards;
and (5) aerosol delivery systems should be well character-
ized including patient interface and should be tested
separately for ventilated as well as for spontaneously
breathing infants. The availability of such delivery systems
for ventilated neonates could optimize the effectiveness of
current aerosolized agents (e.g., bronchodilators, antibiot-
ics, and surfactants) with well-defined safety profiles and,
in addition, may trigger new research to expand its utility
with other therapies and different patient populations.
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